Toward the Development of a Pan-Lyssavirus Vaccine
Viruses · 2024
DOI: 10.3390/v16071107 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Sabrine Ben Hamed und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA. Hauptthemen laut MEDLINE: Lyssavirus, Antibodies, Viral, Rabies virus, Rabies Vaccines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH/NIAID, National Institute of Health (NIH).
Abstract (Originalsprache)
In addition to the rabies virus (RABV), 16 more lyssavirus species have been identified worldwide, causing a disease similar to RABV. Non-rabies-related human deaths have been described, but the number of cases is unknown, and the potential of such lyssaviruses causing human disease is unpredictable. The current rabies vaccine does not protect against divergent lyssaviruses such as Mokola virus (MOKV) or Lagos bat virus (LBV). Thus, a more broad pan-lyssavirus vaccine is needed. Here, we evaluate a novel lyssavirus vaccine with an attenuated RABV vector harboring a chimeric RABV glycoprotein (G) in which the antigenic site I of MOKV replaces the authentic site of rabies virus (RABVG-cAS1). The recombinant vaccine was utilized to immunize mice and analyze the immune response compared to homologous vaccines. Our findings indicate that the vaccine RABVG-cAS1 was immunogenic and induced high antibody titers against both RABVG and MOKVG. Challenge studies with different lyssaviruses showed that replacing a single antigenic site of RABV G with the corresponding site of MOKV G provides a significant improvement over the homologous RABV vaccine and protects against RABV, Irkut virus (IRKV), and MOKV. This strategy of epitope chimerization paves the way towards a pan-lyssavirus vaccine to safely combat the diseases caused by these viruses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Immunology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA.
ORCID-Profile: Jacob F Myers, Drishya Kurup, Nir Paran, Matthias J Schnell
Förderung
- NIH/NIAID
- National Institute of Health (NIH)
Zitieren
APA
Ben Hamed, S., Myers, J. F., Chandwani, A., Wirblich, C., Kurup, D., Paran, N., & Schnell, M. J. (2024). Toward the Development of a Pan-Lyssavirus Vaccine. Viruses. https://doi.org/10.3390/v16071107
Vancouver
Ben Hamed S, Myers JF, Chandwani A, Wirblich C, Kurup D, Paran N, et al. Toward the Development of a Pan-Lyssavirus Vaccine. Viruses. 2024. doi:10.3390/v16071107
BibTeX
@article{BenHamed2024,
author = {Ben Hamed, Sabrine and Myers, Jacob F and Chandwani, Anisha and Wirblich, Christoph and Kurup, Drishya and Paran, Nir and Schnell, Matthias J},
title = {Toward the Development of a Pan-Lyssavirus Vaccine},
journal = {Viruses},
year = {2024},
doi = {10.3390/v16071107}
}
EUVIMED